Actuate Therapeutics Inc. (Ticker: ACTU US) is a pharmaceuticals company developing treatments for cancer, including a glycogen synthase kinase‐3 beta (GSK-3β) drug called elraglusib, which is in a phase 2 trial for pancreatic cancer. Actuate Therapeutics is also initiating studies for elraglusib in refractory Ewing sarcoma.

The firm is offering 5.56 million shares with an expected price range of USD 8.00 to 10.00 per share. The IPO is expected to raise USD 55.56 million. The offering is managed by Titan Partners Group. The expected trading date on Nasdaq is July 18, 2024.